The total return over the past 12 months is -83.36% vs. +16.94% for the S&P 500. So far it's up -54.45% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (83.36%) | (70.60%) | (86.22%) | N/A | N/A | N/A |
| Total Return CAGR | (83.36%) | (70.60%) | (86.22%) | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Ensysce Biosciences, Inc. (ENSC)
| Year | Start price | End price | ENSC Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $0.92 | $0.42 | (54.45%) | +14.51% | (68.96%) |
| 2025 | $8.14 | $0.92 | (88.70%) | +17.72% | (106.42%) |
| 2024 | $15.90 | $8.14 | (48.80%) | +24.89% | (73.69%) |
| 2023 | $135.00 | $15.90 | (88.22%) | +26.19% | (114.41%) |
| 2022 | $16,920.00 | $135.00 | (99.20%) | (18.17%) | (81.03%) |
| 2021 | $44,764.92 | $16,920.00 | (62.20%) | +28.74% | (90.94%) |
| 2020 | $37,512.00 | $44,764.92 | +19.33% | +18.37% | +0.96% |
| 2019 | $35,352.00 | $37,512.00 | +6.11% | +31.22% | (25.11%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
